CN108472275A - 治疗缺血性中风的组合物及方法 - Google Patents

治疗缺血性中风的组合物及方法 Download PDF

Info

Publication number
CN108472275A
CN108472275A CN201680075914.1A CN201680075914A CN108472275A CN 108472275 A CN108472275 A CN 108472275A CN 201680075914 A CN201680075914 A CN 201680075914A CN 108472275 A CN108472275 A CN 108472275A
Authority
CN
China
Prior art keywords
cromolyn
compound
stroke
brain
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680075914.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·埃尔马莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D El Marlay
General Hospital Corp
Original Assignee
Aerts Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerts Treatment Co filed Critical Aerts Treatment Co
Publication of CN108472275A publication Critical patent/CN108472275A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680075914.1A 2015-11-23 2016-11-23 治疗缺血性中风的组合物及方法 Pending CN108472275A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
US62/258,882 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (1)

Publication Number Publication Date
CN108472275A true CN108472275A (zh) 2018-08-31

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680075914.1A Pending CN108472275A (zh) 2015-11-23 2016-11-23 治疗缺血性中风的组合物及方法

Country Status (9)

Country Link
US (2) US20180344682A1 (https=)
EP (1) EP3380095B1 (https=)
JP (1) JP2018538273A (https=)
KR (1) KR20180081812A (https=)
CN (1) CN108472275A (https=)
AU (1) AU2016359674A1 (https=)
CA (1) CA3005909A1 (https=)
MX (1) MX390748B (https=)
WO (1) WO2017091644A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109922800A (zh) * 2016-08-31 2019-06-21 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
CN111629719A (zh) * 2017-12-04 2020-09-04 通用医疗公司 色甘酸组合物及其方法
AU2019251191A1 (en) * 2018-04-09 2020-10-29 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof
WO2025235823A1 (en) * 2024-05-08 2025-11-13 The Johns Hopkins University Compositions and methods for treatment of neuronal injury and neurode generative disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276455A1 (en) * 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20140140927A1 (en) * 2009-01-29 2014-05-22 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015061397A1 (en) * 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005019582D1 (de) * 2004-08-30 2010-04-08 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
US8617517B2 (en) * 2009-01-29 2013-12-31 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
TWI541021B (zh) * 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
AU2010224184A1 (en) * 2009-03-11 2011-09-29 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of Raf kinases
EP3563849A3 (en) * 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
PL3104853T3 (pl) * 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
JP2019524865A (ja) * 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276455A1 (en) * 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20140140927A1 (en) * 2009-01-29 2014-05-22 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015061397A1 (en) * 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱照静等主编: "《药剂学》", 31 August 2007 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109922800A (zh) * 2016-08-31 2019-06-21 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
CN109922800B (zh) * 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞

Also Published As

Publication number Publication date
MX390748B (es) 2025-03-21
WO2017091644A1 (en) 2017-06-01
US20220125753A1 (en) 2022-04-28
MX2018006390A (es) 2019-02-14
US20180344682A1 (en) 2018-12-06
EP3380095A1 (en) 2018-10-03
EP3380095A4 (en) 2019-10-23
EP3380095B1 (en) 2022-01-05
JP2018538273A (ja) 2018-12-27
KR20180081812A (ko) 2018-07-17
CA3005909A1 (en) 2017-06-01
AU2016359674A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
US20220125753A1 (en) Compositions and methods for treating ischemic stroke
JP2025118786A (ja) 安定なカンナビノイド製剤
US20220054450A1 (en) Stable cannabinoid formulations
CA2928028A1 (en) Cromolyn derivatives and related methods of imaging and treatment
CA3236069A1 (en) Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
EP2184063A1 (en) The use of leonurine and compositions thereof
CN111840112B (zh) 鼠尾草酸或其衍生物在制备治疗糖尿病并发症药物中的应用
CN120265283A (zh) (-)-表没食子儿茶素没食子酸酯类化合物的应用
JP6258264B2 (ja) ヒトの血小板レベルを増加させるための組成物および方法
US9066942B2 (en) Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
CN109369754B (zh) 硝酸酯类化合物及其应用
WO2022238884A1 (en) Dosing regimens
CN114903910A (zh) 芹菜素-7-O-β-D-葡萄糖苷在制备炎症性肠病治疗药物中的应用
JP2023550407A (ja) 肺高血圧向けの吸入式イマチニブ
RU2181286C2 (ru) Кардиотоническое и гипертензивное средство, длительно повышающее давление, и лекарственные формы на его основе
JP7257091B2 (ja) 認知症の治療及び予防薬
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
KR20250173974A (ko) 엠파글리플로진 및 텔미사르탄을 함유하는 대사이상 관련 지방성 간질환 예방 또는 치료용 약학적 조성물
WO2023221793A1 (zh) 一种酚酸衍生物用于治疗缺血性脑卒中的应用
KR101516452B1 (ko) 관동맥의 묘출능 개선제
Mouihate et al. FINAL ACCEPTED VERSION R-00250-2006. R1
JPS59134722A (ja) 出血性梗塞予防・治療剤
HK1170673B (en) Compositions and methods for increasing blood platelet levels in humans
KR20130038583A (ko) 소포체 스트레스 억제제를 유효성분으로 함유하는 급성 폐 손상의 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210929

Address after: Massachusetts, USA

Applicant after: D El Marlay

Address before: Massachusetts, USA

Applicant before: AZTherapies, Inc.

Effective date of registration: 20210929

Address after: Massachusetts, USA

Applicant after: THE GENERAL Hospital Corp.

Address before: Massachusetts, USA

Applicant before: D El Marlay

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180831

WD01 Invention patent application deemed withdrawn after publication